- Tongwei is projecting a preliminary net loss ranging from 4.9 billion yuan to 5.2 billion yuan for the first half of the year.
- The company attributes its loss to ongoing issues in the photovoltaic industry, specifically citing an imbalance between supply and demand.
- Despite the financial losses, market analysts maintain mixed ratings on Tongwei, with 18 buy recommendations, 4 hold recommendations, and 6 sell recommendations.
A look at Tongwei Co Ltd A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
In assessing Tongwei Co Ltd A using Smartkarma Smart Scores, the company emerges with a positive outlook overall. With a strong emphasis on dividends and value, Tongwei Co Ltd A scores high in these areas. Investors looking for stable returns and value in their investments may find Tongwei Co Ltd A appealing based on these scores. Additionally, the company shows promising momentum, indicating a positive trend in its performance. However, in terms of growth and resilience, Tongwei Co Ltd A scores lower, suggesting areas where the company may need further development to secure its long-term success.
Tongwei Co Ltd A, a producer and marketer of aquatic and animal feeds, along with the sale of animal medicines, positions itself as a key player in the industry. With its strong emphasis on dividends and value, Tongwei Co Ltd A provides investors with an opportunity for steady returns and an attractive valuation. While growth and resilience scores are not as high, the company’s momentum reflects positive performance trends. Investors considering Tongwei Co Ltd A for their portfolio may find its focus on dividends and value aligning with their long-term investment goals.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
